Understanding Appetite & Opportunities for Plain Language Summaries (PLS)

Taylor & Francis

Kelly A. Soldavina, Jonathan Patienceb and Priti Nagdab

^aTaylor & Francis Group, Philadelphia, PA, USA; ^bTaylor & Francis Group, London, UK

Fo Plant Control of the Control of t

For further information, please contact PlainLanguageSummaries@taylorandfrancis.com

This poster can be downloaded via the Quick Response (QR) code. These copies are for personal use only and may not be reproduced without written permission from the authors.

Figure 1b. Are you or your clients/employer

Objective

- Publication of PLS is encouraged in publication guidelines for biomedical research^{1,2} and supported by publication stakeholders³.
- Our aim was to investigate stakeholder approaches to PLS and assess opportunities for PLS resources.

Research design & methods

An online survey (13 questions) was distributed to publication professionals via email, social media and the ISMPP Connect forum over 3 months (December 2022–February 2023).

Results

- Of 65 respondents, 28 (43.1%) were affiliated with pharma, 22 (33.9%) with medcomms and 15 (23.1%) with publishing, academia, HEOR and patient advocacy; 58 (89.2%) indicated their clients/employers were publishing PLS (**Figure 1a & 1b**).
- Preferred digital enhancements were graphical PLS (66.2%) and abstracts (64.6%), text PLS (63.08%) and infographics (47.7%).
- Target audiences for PLS included HCPs/non-specialist clinicians (84.6%), patients (78.5%), patient advocates and caregivers (76.9%) and general lay audiences (67.7%) (**Figure 2**).
- PLS were published to extend reach of study findings (87.7%), facilitate accurate communication of medical information (70.8%) and improve awareness of therapies (69.2%).
- Barriers to PLS publication included lack of journal PLS mandates (64.6%), clarity regarding which journals publish PLS (52.3%), information/support from publishers (41.5%), stakeholder buy-in (38.5%) and time/funding (35.4%) (Figure 3a & 3b).
- Respondents ranked PubMed indexing, publisher dissemination, post-publication submission and online databases as the most important (scores >4.9) PLS resources/services (Figure 4).

Conclusions

This survey suggests that PLS are considered an essential publication enhancement by publication stakeholders. Key opportunities include:

- Improved publisher information and support
- Stakeholder collaboration on discoverability
- Enhanced health literacy through patient partnership
- Online repository/database archive for PLS publications.

Figure 1a. Respondents' roles/employers





Figure 2. Target audiences for PLS

(shown as percentage of respondents who selected answer)

Figure 3a. Barriers to publication of PLS



(shown as number of respondents who selected answer) N=65 Figure 3b. How to you determine which Lack of journal PLS requirement publishers/journals offer PLS? Not clear which journals (shown as number of respondents who selected answer) publish PLS Not enough info/support Publisher/journal website **57 27** from publishers Query to journal editorial staff Limited stakeholder buy-in **25** Word of mouth from colleagues Lack of resources (time/funding) Query to authors, sponsor, Compliance concerns medcomms Difficulty writing in Search engine (e.g., Google)

Figure 4. PLS resources/services ranked by importance

(ranked from most important to least important)

Other

plain language

- PubMed indexing of PLS
- 2. Publisher dissemination to intended audience
- 3. Post-publication submission of PLS (after article publication)
- 4. Searchable online database of published PLS
- 5. Visible metrics for PLS views/downloads
- 6. Patient advisory boards, peer reviewers and authors
- 7. Services for writing and creating PLS
- 8. Educational resources and webinars on PLS

"Having PLS freely and easily available is critical. Putting them behind a paywall is obviously a bad practice, but even a site that requires free registration adds a burden to patients trying to access information."

– Survey respondent

ISMPP EPON

Other

References. 1. DeTora L, et al. Ann Intern Med 2022;175(9):1298–1304.; 2. Rosenberg A, et al. Curr Med Res Opin 2021;37(11):2015–16.; 3. Lobban D, et al. Curr Med Res Opin 2022;8(2):189-200.

Author Contributions. All authors contributed to study design, data analysis, interpretation of results and drafting and revising of the publication, as well as provided final approval of the version submitted for publication.

Disclosures. All authors are employed by Taylor & Francis Group, publisher of Current Medical Research and Opinion, which publishes the abstracts from the European and Annual Meetings of ISMPP. KS serves on the ISMPP Board of Trustees.

Abbreviations. HCP: healthcare professional; HEOR = health economics and outcomes research; medcomms = medical communication agencies; pharma = pharmaceutical companies; PLS = plain language summaries. **Acknowledgements.** The authors thank Tobi Dumbraveanu and Sam Cavana of Future Science Group/Taylor & Francis and Caroline Halford of Springer Healthcare for the assistance with figure and infographic creation and poster formatting and design.